Dec 20 (Reuters) - Teva Pharmaceuticals (TEVA.TA), opens new tab failed to convince a U.S. appeals court on Friday to reverse a decision that would remove patents related to its ProAir HFA inhaler ...

“In the United States, while 93% of Teva’s inhaler medicines are generic products with access at lower prices – particularly for insured patients – there still remain uninsured patients ...

Amneal plans to market a generic version of the inhaler and had argued that Teva’s patents were incorrectly included on the FDA list. The order posted to the site of the court states ...

Teva has launched a digitally-enabled inhaler in the UK, the first European market for the device, for use by patients with asthma and chronic obstructive pulmonary disorder (COPD). The GoResp ...

Despite news of losing the bid against Amneal Pharmaceuticals and having to remove incorrect patents for an inhaler product, shares of Teva recorded an increase of 33.79 percent in the past ...

“In the United States, while 93% of Teva’s inhaler medicines are generic products with access at lower prices – particularly for insured patients – there still remain uninsured patients who cannot ...